Cargando…
Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Do...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912822/ https://www.ncbi.nlm.nih.gov/pubmed/24511390 http://dx.doi.org/10.1155/2014/710401 |
_version_ | 1782302142985404416 |
---|---|
author | Kobak, Senol Kalkan, Sezai Kirilmaz, Bahadır Orman, Mehmet Ercan, Ertuğurul |
author_facet | Kobak, Senol Kalkan, Sezai Kirilmaz, Bahadır Orman, Mehmet Ercan, Ertuğurul |
author_sort | Kobak, Senol |
collection | PubMed |
description | Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Doppler echocardiography is an important, noninvasive screening test for PAH diagnosis. Objective. The aim of this present study is to define the frequency of PAH in patients with pSS and to reveal correlations with laboratory and clinical findings. Material and Methods. A total of 47 patients, who were diagnosed with pSS according to American-European Study Group criteria were enrolled in the study. After all patients were evaluated clinically and by laboratory tests, Doppler echocardiography was performed in the cardiology outpatient clinic. Systolic pulmonary artery pressure (SPAP) >30 mm Hg values, which were measured at the resting state, were accepted as significant for PAH. Results. Forty-seven patients with pSS were included in the study. The mean age of patients was 48 years and the mean disease duration was 5.3 years. PAH was defined in 11 of the 47 patients (23.4%). The SPAP value was over 35 mm Hg in 5 out of 11 patients, whereas six patients had SPAP measuring 30–35 mm Hg. While pulmonary hypertension was related with earlier age and shorter duration of disease (P = 0.04), there was no statistically significant correlation between SPAP increase and clinical findings (P > 0.05). Conclusion. We have defined high PAH frequency in patients with pSS. Since there are different data in the literature, it is obvious that large scale, multicentre studies are required. |
format | Online Article Text |
id | pubmed-3912822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39128222014-02-09 Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome Kobak, Senol Kalkan, Sezai Kirilmaz, Bahadır Orman, Mehmet Ercan, Ertuğurul Autoimmune Dis Clinical Study Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Doppler echocardiography is an important, noninvasive screening test for PAH diagnosis. Objective. The aim of this present study is to define the frequency of PAH in patients with pSS and to reveal correlations with laboratory and clinical findings. Material and Methods. A total of 47 patients, who were diagnosed with pSS according to American-European Study Group criteria were enrolled in the study. After all patients were evaluated clinically and by laboratory tests, Doppler echocardiography was performed in the cardiology outpatient clinic. Systolic pulmonary artery pressure (SPAP) >30 mm Hg values, which were measured at the resting state, were accepted as significant for PAH. Results. Forty-seven patients with pSS were included in the study. The mean age of patients was 48 years and the mean disease duration was 5.3 years. PAH was defined in 11 of the 47 patients (23.4%). The SPAP value was over 35 mm Hg in 5 out of 11 patients, whereas six patients had SPAP measuring 30–35 mm Hg. While pulmonary hypertension was related with earlier age and shorter duration of disease (P = 0.04), there was no statistically significant correlation between SPAP increase and clinical findings (P > 0.05). Conclusion. We have defined high PAH frequency in patients with pSS. Since there are different data in the literature, it is obvious that large scale, multicentre studies are required. Hindawi Publishing Corporation 2014 2014-01-09 /pmc/articles/PMC3912822/ /pubmed/24511390 http://dx.doi.org/10.1155/2014/710401 Text en Copyright © 2014 Senol Kobak et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Kobak, Senol Kalkan, Sezai Kirilmaz, Bahadır Orman, Mehmet Ercan, Ertuğurul Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome |
title | Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome |
title_full | Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome |
title_fullStr | Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome |
title_full_unstemmed | Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome |
title_short | Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome |
title_sort | pulmonary arterial hypertension in patients with primary sjögren's syndrome |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912822/ https://www.ncbi.nlm.nih.gov/pubmed/24511390 http://dx.doi.org/10.1155/2014/710401 |
work_keys_str_mv | AT kobaksenol pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome AT kalkansezai pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome AT kirilmazbahadır pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome AT ormanmehmet pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome AT ercanertugurul pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome |